ClinicalTrials.gg
RecruitingNCT07861932PIKYMA-01Updated Nov 17, 2026

A Phase 1/2a Study of K-1728 in Advanced Solid Tumors

A Phase 1/2 interventional study of K-1728 and Fulvestrant in Breast Neoplasms, Solid Tumors and PIK3CA Gene Mutation, sponsored by KymaThera, Inc.. Recruiting at 2 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by KymaThera, Inc. · Phase 1/2, Interventional, and Treatment

How we know · 8 judgments

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 17, 2026Now RecruitingFirst site in Australia+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
110
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 403 studies in Breast Neoplasms with a site in Australia — 85 open to participants now, 156 under way, 61 of them phase 3. Breast Neoplasms · Australia.

Planned enrollment
265th of 381
110 · median 252
Started
2026
with 16 others
Phase 1/2
42 of 403
18 open now
Primary completion
2028-09
later than 113 of 155 live
Registered
402nd of 403
by date

Among the 403 studies in Breast Neoplasms with a site in Australia, this one is the 265th largest by planned enrollment of the 381 interventional ones that give a count, is one of 17 that started in 2026, is one of 42 in phase 1/2, reaches primary completion later than 113 of the 155 other live ones, and was the 402nd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

85 of the 403 studies in Breast Neoplasms with a site in Australia are open now. Recruiting first, the newest first:

79 more — sign in →

All 85 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 403 studies in Breast Neoplasms with a site in Australia, or all of them as a file.
02

Study summary

This first-in-human, open-label, multicenter study evaluates K-1728 administered as monotherapy and in combination in participants with advanced or metastatic solid tumors. The study assesses the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of K-1728.

03

Conditions studied

  • Breast Neoplasms
  • Solid Tumors
  • PIK3CA Gene Mutation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Adults with advanced or solid tumors who are able to provide consent
  • Documented activating PIK3CA mutation
  • performance status 0 or 1
  • Adequate organ function

Key Exclusion Criteria:

  • Active or untreated central nervous system disease
  • Clinical significant or uncontrolled cardiovascular disease
  • Significant or uncontrolled intercurrent illness
  • Pregnant or breastfeeding
  • Other protocol-defined exclusion criteria
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    K-1728 Monotherapy

    Participants receive K-1728 orally as monotherapy

    Drug: K-1728

  • Experimental
    K-1728 + Endocrine Therapy

    Participants receive K-1728 orally in combination with endocrine therapy

    Drug: K-1728 · Drug: Fulvestrant

  • Experimental
    K-1728 + Endocrine Therapy + CDK4/6 Inhibitor

    Participants receive K-1728 orally in combination with endocrine therapy and a CDK4/6 inhibitor

    Drug: K-1728 · Drug: Fulvestrant · Drug: Palbociclib

Interventions

  • DrugK-1728

    K-1728 will be administered orally once daily in 28-day cycles

  • Fulvestrant will be administered intramuscularly on Days 1 and 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle

  • Palbociclib will be administered orally on Days 1-21 in 28-day cycles

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD)/Maximum Efficacious Dose (MED) and Recommended Phase 2 Dose (RP2D)

    Determination of the MTD/MED and RP2D of K-1728 administered as monotherapy and in combination

    Time frame: Cycle 1 (28 days) through completion of dose escalation (up to approximately 24 months)

  2. Incidence of Dose-Limiting Toxicities (DLTs)

    Number and percentage of participants experiencing a dose-limiting toxicity during the DLT-evaluation period with of K-1728 administered as monotherapy and in combination

    Time frame: Initiation of study drug through Cycle 1 (28 days)

  3. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Number and percentage of participants with adverse events and serious adverse events with K-1728 administered as a monotherapy and in combination

    Time frame: From first dose through 30 days after the last dose of study treatment (up to approximately 24 months)

  4. Changes in laboratory parameters

    Compared to baseline, changes in laboratory parameters with K-1728 administered as monotherapy and in combination

    Time frame: From first dose through 30 days after the last dose of study treatment (up to approximately 24 months)

  5. Changes in vital signs

    Compared to baseline, changes in vital signs with K-1728 administered as monotherapy and in combination

    Time frame: From first dose through 30 days after the last dose of study treatment (up to approximately 24 months)

  6. Changes in electrocardiogram (ECG) parameters

    Compared to baseline, changes in ECG parameters (including QT interval, QTc interval, QRS complex, and PR interval)

    Time frame: From first dose through 30 days after the last dose of study treatment (up to approximately 24 months)

  7. Changes in physical examination

    Compared to baseline, changes in physical examination

    Time frame: From first dose through 30 days after the last dose of study treatment (up to approximately 24 months)

Secondary outcomes

  1. Pharmacokinetics - Maximum Plasma Concentration (Cmax) of K-1728

    Cmax of K-1728 when administered as monotherapy or in combination

    Time frame: Approximately every 2 weeks in Cycle 1 (4-week cycle) and every cycle until end of treatment, approximately 24 months

  2. Pharmacokinetics - Time to Maximum Plasma Concentration (Tmax) of K-1728

    Tmax of K-1728 when administered as monotherapy or in combination

    Time frame: Approximately every 2 weeks in Cycle 1 (4-week cycle) and every cycle until end of treatment, approximately 24 months

  3. Pharmacokinetics - Area Under the Plasma Concentration-Time Curve (AUC) of K-1728

    AUC of K-1728 when administered as monotherapy or in combination

    Time frame: Approximately every 2 weeks in Cycle 1 (4-week cycle) and every cycle until end of treatment, approximately 24 months

  4. Pharmacokinetics - Half-life (t1/2) of K-1728 when administered as monotherapy or in combination

    t1/2 of K-1728 when administered as monotherapy or in combination

    Time frame: Approximately every 2 weeks in Cycle 1 (4-week cycle) and every cycle until end of treatment, approximately 24 months

  5. Preliminary Efficacy - Overall Response Rate (ORR)

    Objective Response Rate (ORR) as assessed by RECIST v1.1

    Time frame: Initiation of study drug until disease progression, assessed up to approximately 24 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Sep 2028, 23 months after the start.

Of 164 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 23 months is below that.

Counting every sponsor, half of 331 studies reached it within 62 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Oct 6, 2026
StartActual
Oct 14, 2026
Primary completionEst.
Sep 2028
CompletionEst.
Mar 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 17, 2026
Sites
2 sites added — first site in Australia
Show 2 added (2 Australia)
  • Scientia Clinical Research · Randwick, Australia
  • Linear Clinical Research · Nedlands, Australia
Nov 17, 2026
Registered
First appeared on the registry
Oct 6, 2026
Show all 2 updates
  1. Nov 17, 2026
    Not yet recruiting→Recruiting
    2 sites added — first site in Australia
    Show 2 added (2 Australia)
    • Scientia Clinical Research · Randwick, Australia
    • Linear Clinical Research · Nedlands, Australia
    + 1 other change: date precision
  2. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07861932
Lead sponsor
KymaThera, Inc.
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Oct 14, 2026
Primary completion
Sep 2028 (estimated)
Completion
Mar 2029 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion